Australian Biotech CSL Sees Upbeat 2024

Australian biotech giant CSL on Tuesday forecast increased earnings in fiscal 2024 for all its segments on strong demand and cost cutting.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/995464?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost